Company intelligence / Profile preview

BLES Biochemicals Inc.

London, Ontario, Canadablesbiochem.com ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

BLES Biochemicals’ lead product, BLES® (bovine lipid extract surfactant), is approved by Health Canada and has been shown in a Phase III randomized, comparative, double-blind, multi-dose, multi-centre trial to be significantly more effective than Exosurf®, with reduced mortality and morbidity and improved oxygenation in premature infants with NRDS. The company’s products are market leaders in Canada and are distributed globally.

Therapeutic areas: Pulmonology
Modalities: Biologic drug (bovine lipid extract surfactant)Medical device (catheter for surfactant delivery)
Industry: Biotech

Drug pipeline

1 asset

BLES

Beyond the preview

Go deeper on BLES Biochemicals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLES Biochemicals Inc..